Anti-TSHR Antibody (K1-70) is an anti- TSHR monoclonal antibody. Anti-TSHR Antibody (K1-70) incorporates a single-chain variable fragment into a chimeric antigen receptor to redirect T cells to TSHR-expressing cells. Anti-TSHR Antibody (K1-70) shows antitumor activity with no apparent toxicity. Anti-TSHR Antibody (K1-70) can be used for the research of differentiated thyroid cancer (DTC) [1].
In Vivo, Anti-TSHR Antibody (K1-70) (5×106 70-CAR T cells; i.v.; single dose) induces significant DTC tumor regression, prolongs mouse survival, and exhibits a favorable safety profile in the NSG mouse xenograft model[1].
In Vitro, Anti-TSHR Antibody (K1-70) can be used to generate anti-TSHR CAR-T cells, which exhibit robust proliferative capacity, lower apoptosis levels, and can maintain a memory-like CD8+ T cell subset with a less differentiated state[1].
References:
[1]. Li H, et al. CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022;107(4):1110-1126.
In Vivo, Anti-TSHR Antibody (K1-70) (5×106 70-CAR T cells; i.v.; single dose) induces significant DTC tumor regression, prolongs mouse survival, and exhibits a favorable safety profile in the NSG mouse xenograft model[1].
In Vitro, Anti-TSHR Antibody (K1-70) can be used to generate anti-TSHR CAR-T cells, which exhibit robust proliferative capacity, lower apoptosis levels, and can maintain a memory-like CD8+ T cell subset with a less differentiated state[1].
References:
[1]. Li H, et al. CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2022;107(4):1110-1126.